Note: Descriptions are shown in the official language in which they were submitted.
CA 022~2141 1998-10-26
METHOD AND DEVICE FOR THE
DETECTION OF ANALYTE IN A FLUID SAMPLE
Backqround of the Invention
There is a need for simple diagnostic tests for common
diseases that can be executed by untrained personnel. Simpler
tests would allow for home or doctor's office testing when
current procedures require the analysis to be done by an out-
side laboratory. Possible benefits of simpler tests are de-
creased turnaround time and a reduction in cost. Representa-
tive examples are home pregnancy and glucose testing.
A common format for these simpler tests is the immunos-
trip format. Usually this format contains a mobile phase con-
sisting of the test solution and a labeled, analyte-specific
antibody. The analyte binds to the antibody and passes
through a capture zone which contains immobilized analyte or
an analyte derivative which is immunologically reactive with
the antibody. The capture zone removes excess labeled anti-
body as the bound labeled antibody migrates to a detection
zone.
There are numerous analytes whose detection by such a di-
agnostic test could benefit the public. Accurate, stable and
reproducible tests are highly desirable. By using the osteo-
porosis marker deoxy-pyridinoline, which is illustrative of
analytes, it is the intent of this invention to describe poly-
mer-bound analytes that provide advantages when used to immo-
bilize the analyte onto the immunostrip's capture zone.
CA 022~2141 1998-10-26
Collagen is present in various forms in all tissue. It
is now well accepted that collagen has the form of amino acid
chains cross-linked by the pyridinium crosslinks pyridinoline
(PYD) and deoxypyridinoline (DPD). The pyridinium crosslinks
are formed from three hydroxylysine residues, two of which are
from the terminal (non-helical) peptides of the collagen mole-
cule that are enzymatically converted to aldehydes before re-
action and a third hydroxylysine situated in the helical por-
tion of a neighboring collagen molecule. There have been de-
scribed techniques in the literature for the measurement of
pyridinoline in urine by use of an enzyme labeled antibody
specific to pyridinoline to form a pyridinoline-enzyme labeled
complex which can be detected by an enzyme-linked immunosor-
bant assay. While the analysis for PYD is useful as a means
of screening for osteoporosis and rheumatoid arthritis, its
presence in connective tissue, as well as in bone, can cause
skewed results. Accordingly, immunoassays for deoxypyridino-
line, which is only found in bone, have become preferred over
those for PYD in the early detection of bone degradation.
Testing for DPD can be accomplished by contacting a fluid
test sample, e.g. urine, with a labeled antibody specific for
DPD. A particularly convenient method for DPD determination
involves the use of a test strip of the type depicted in Fig.
1. Referring to Fig. 1, strip 10 having a labeled anti-DPD
antibody complex (typically with gold sol as the labeling ma-
terial) binds with DPD in the fluid test sample in application
zone 12 of the strip 10. The labeled DPD antibody and DPD in
the fluid test sample which is applied to the application zone
12 of the strip 10 form an immunocomplex which migrates due to
CA 022~2141 1998-10-26
capillary action through the capture zone of the strip 14 and
the optional detection zone 16. In the capture zone 14, there
is immobilized DPD which captures unbound, labeled anti-DPD.
The signal generated by the label on the captured anti-DPD is
measured, such as by means of a reflectance spectrophotometer,
and correlated with the results of replicate strips used to
assay fluid test samples containing known amounts of DPD. As
in classical competitive immunoassays, the intensity of the
signal generated in the capture zone will be inversely propor-
tional to the concentration of the DPD in the fluid sample.
Labeled anti-DPD, which is not captured in the capture zone 14
because it had combined with DPD in the fluid test sample, is
captured in the detection zone 16 by anti-mouse IgG, specific
for a different epitope on the anti-DPD antibody than the pre-
viously mentioned active binding site for DPD on the labeled
anti-DPD, which is immobilized in this zone. By measuring the
spectral response from the capture and detection zones, and
analyzing this response using an appropriate algorithm, the
accuracy of the assay can be increased.
Nitrocellulose, commonly used to bind proteins and
poly(ethylene glycols), is a preferred material for use in
preparing the type of test strip illustrated by Fig. 1. Poly-
sulfones, nylons or other porous membranes capable of adsorb-
ing macromolecules also provide suitable strip material. A
common technique to immobilize an analyte onto nitrocellulose
or other solid support is to covalently bind the analyte to a
protein that irreversibly adsorbs onto the solid support. Ap-
plying the resulting conjugate to the solid support results in
an irreversibly bound analyte.
CA 022~2141 1998-10-26
To provide a quality product, sensitivity, stability and
precision are highly desirable. The object of this invention
is to provide conjugates which provide such sensitivity, sta-
bility and precision.
Summary of the Invention
The present invention is an improvement to an immunoassay
technique for an analyte in a fluid test medium in which a la-
beled antibody specific to the analyte is combined with the
fluid test medium and the fluid test medium is then contacted
with a solid support upon which the analyte or analyte deriva-
tive is immobilized. In this type of immunoassay, labeled an-
tibody which has not reacted with the analyte in the test me-
dium will react with and be bound by the immobilized analyte
or derivative thereof. The improvement involves immobilizing
the analyte or derivative onto the solid support using a con-
jugate prepared by reacting the analyte or derivative with
polyethylene glycol functionalized on one or both ends with a
group which is reactive for the analyte or derivative. When
the polyethylene glycol is functionalized on only one end with
the reactive group, it is functionalized on the other end with
an unreactive capping group. The reactive group acts to bind
the analyte or analyte derivative to the solid support.
Description of the Invention
A format in which the present invention can be carried
out is illustrated by Fig. 1. For purposes of this discussion
the analyte is DPD, but it is to be understood that other ana-
. . . .
CA 022~2141 1998-10-26
lyte are also detectable by using analogous systems. A gold
sol anti-DPD antibody complex binds DPD in the fluid test sam-
ple and migrates through the strip's zones. In the first
zone, capture zone 14, immobilized DPD captures unbound gold
sol/anti-DPD complex. The second zone, detection zone 16,
containing goat anti-mouse IgG, captures the gold sol/anti-DPD
that did not bind to DPD in the detection zone. The concen-
tration of DPD in the fluid test sample can be determined by
an algorithmic treatment of the reflectance measurements of
the two zones. Capture zone 14 requires immobilized DPD. Bo-
vine serum albumin (BSA) and polyethylene glycol (PEG) conju-
gates were prepared, optimized and immobilized on capture zone
14 of the nitrocellulose strip using the following technique:
Preparation of BSA-DPD conjugate: 1-(3-Dimethylamino-
propyl)-3-ethyl carbodiimide (140 mg) was added to an ice cold
solution consisting of 36 mg of bovine serum albumin (Bayer
Pentex~, fraction V, protease free), 16 mg of sulfo N-
hydroxysuccinimide and 3 mL of 100 mM, pH 8, EPPS. The solu-
tion was stirred 15 minutes at room temperature and cooled in
an ice bath. The mixture was then added to a chilled solution
of 4.4. mg of DPD in 6.28 mL of 10 mM HCl and allowed to stir
for 4.5 hours in an ice bath. After 5~ C overnight storage,
26 mL of a 40 ~M solution of lysine hydrochloride was added
and the mixture stirred for 4 hours at room temperature. In a
50 mL Amicon stirred ultrafiltration unit, the reaction was
concentrated and diluted four times with 50 mL of pH 7.4 PBS
using a Amicon YM-30 membrane. The retentate was chroma-
tographed on a 3 x 25 cm Sephadex G-25 column. Fractions 10-
14 (6 mL fractions) contained the product as determined by W
monitoring. These were combined to provide a 1.2 mg/mL solu-
CA 022~2141 1998-10-26
tion of BSA-DPD with an absorbance at 324 nm of 0.29 indicat-
ing a DPD to BSA ratio of 2.75. The PEG-DPD conjugate was
prepared as described in the following Example IA.
Stability and precision data are presented in Table 1. A
dose response curve for the PEG immobilized DPD is presented
in Fig. 2.
TABLE 1
Comparison of Precision and Stability Between
BSA and PEG Conjugates
DPD Co, _ - Preasion Stabili~y at 40 ~C %(~ias)
DPD nM~%C'J1~5)1~ek ~.~eek
BSA-DPD 3 - 9% ~7%
1C~ 0% - 6%
PEG-DPD 3 .6 1% 3%
1 ~ .2 -5% 2%
The data of Table 1 reveal that the PEG conjugates pro-
vide better precision and stability than the conjugates pre-
pared using BSA as indicated by lower coefficients of varia-
tion and bias numbers. Better stability and precision indi-
cate that the PEG conjugates are preferred in this formula-
tion. Suitable for use in the present invention are polyeth-
ylene glycols of molecular weight greater than about 6,000.
The preferred molecular weight is about 20,000 with a maximum
molecular weight of about 35,000 being preferred. Polyethyl-
ene glycols with molecular weights up to 50,000 and greater
may be used, however, the ability of the PEG conjugate to bind
the analyte or analyte derivative drops off at these higher
molecular weights.
CA 022~2141 1998-10-26
The PEG is typically terminated at both ends with the
analyte interactive functional group. It can, however, be
terminated at one end with the functional group and on the
other with an unreactive capping group such as an alkyl
(preferably methyl) ether. Suitable reactive groups include
activated carboxy, amino, epoxy, halo, sulfhydryl, isocyanate,
maleimide and formyl.
When the analyte or derivative thereof bears one or more
amino group, the reactive group on the polyethylene glycol can
be epoxy, halo, isocyanate or activated carboxy due to the
ability of these groups to form stable bonds with amines.
Likewise, when the PEG is amine terminated and the analyte
bears carboxyl groups, the binding between the PEG and the
analyte is carried out using an activating agent such as
thionyl chloride, N,N,N',N',-tetramethyl(succinimido) uronium
tetrafluoroborate, isobutylchloroformate or N,N-
dialkylcarbodiimide, in the presence of N-hydroxy-succinimide,
p-nitrophenol, pentafluorophenol or pentachlorophenol.
When the reactive group on the PEG is formyl, it is com-
bined with an amine bearing analyte or analyte derivative in
the presence of a reducing agent to bind the analyte to the
PEG through the amine. Suitable reducing agents include so-
dium cyanoborohydride and Pd/C with H2.
In addition, the reactive group on the PEG can be a sulf-
hydryl when the analyte or derivative thereof bears a
maleimide group or vice-versa so that the analyte is bound to
the polymer via a 4-succinimide sulfide linkage.
.
CA 022~2141 1998-10-26
Common methods of preparing analyte/polymer conjugates
suitable for immobilizing the analyte to a solid support in-
volve the reaction of proteins such as BSA with analytes in
the presence of carbodiimides. In the case of amino acid
bearing analytes, these reaction conditions cause the polym-
erization of the analyte through reaction of its amino and
carboxylate groups. This problem can be circumvented by puri-
fying the activated protein intermediate, however, this makes
the procedure more time consuming due to the extra steps in-
volved. The preactivated PEG reagents of the present inven-
tion react directly with the amino groups of amino acid bear-
ing analytes to form conjugates without an intermediate puri-
fication step. Other advantages are that there is no polym-
erization of the analyte, this unreacted analyte can be recov-
ered, and the reaction can be carried out under anhydrous con-
ditions which allow a higher percentage of incorporation of
the analyte into the polymer which is especially useful when
the analyte is not readily available.
In early experiments, the PEG polymer used to form a con-
jugate with DPD had a molecular weight of 3400. Evaluation of
this conjugate indicated that it bound a gold sol/anti-DPD
complex in the presence of nitrocellulose but not in the pres-
ence of free DPD. From this it was concluded that either the
conjugate did not bind the gold sol/anti-DPD conjugate tightly
or the conjugate did not bind tightly to the nitrocellulose.
As an alternative to the use of the 3400 molecular weight PEG,
there was employed a higher molecular weight PEG (MW 20,000)
which was found to absorb onto the nitrocellulose and bind un-
bound gold sol/DPD antibody conjugates. A dose response curve
CA 022~2141 1998-10-26
using 20,000 MW PEG-DPD conjugates in capture zone 14 is shown
in Fig. 2.
The present invention is further illustrated by the fol-
lowing examples:
Example I (Preparation of PEG-DPD Conjugates)
A. Preparation of PEG(MW 20,000)-DPD Conjugate
To 100 ~L of 0.1 M, pH 8.0 4-(2-hydroxyethyl)-1-
piperazine propane sulfonic acid (EPPS) was added 32 ~L (0.198
y mole) of a 2.55 mg/mL solution of DPD which had been iso-
lated from bone. Meanwhile, a 20 mg/mL solution of PEG(MW
20,000) bis N-hydroxy-succinnimidyl ester was prepared in di-
methylformamide (DMF) and 100 ~L (0.1 ~ mole) added to the DPD
mixture. The reaction was allowed to stir at room temperature
for 18 hours and was then purified by repeated (7X) concentra-
tion through a YM-3 membrane from Amicon followed by redilu-
tion with pH 7.4 (0.01 M) phosphate buffered saline (PBS)
buffer. The retentate (1.86 mL) had an absorbance at 326 nm
of 0.138. Assuming an 80% recovery of polymer, this absorp-
tion value indicates 0.7 DPD/PEG, i.e. an average of 0.7 DPD
molecules bound to one PEG molecule.
B. Preparation of PEG(MW 50,000)-DPD Conjuqate
A 40 ~L sample of a 2.55 mg/mL solution of DPD was ly-
ophilized and 200 yL of a solution comprising 0.54 ~L/mL of
triethylamine (0.784 ~ mole) in DMF was added to the residue.
As a solid, 67.1 mg (0.12 ~ mole) of PEG (50,000) bis N-
CA 022~2141 1998-10-26
hydroxysuccinnimidyl ester was added and the mixture allowed
to stir for 18 hours at room temperature. It was purified as
described above except that a YM30 membrane from Amicon was
used. The absorbance at 326 nm of a 1.6 mL solution of the
retentate was 0.1 after compensation for the baseline. Assum-
ing 80% recovery of the polymer, the DPD/PEG ratio was 0.38
The immobilization of DPD with the 50,000 MW PEG was not as
effective as when lower molecular weight polymers were used,
indicating the desirability of using lower molecular weight
polymers.
Example II (Preparation of the Reagent Pad)
Reagents were deposited onto nitrocellulose membranes (16
cm x 6 cm) in the following manner:
Two bands of anti-mouse IgG (1 mg/mL of PBS) were depos-
ited onto the nitrocellulose at about 3 and 3.5 cm from the
bottom of the membrane and at amounts of 2 yL/cm and 1 yL/cm
respectively. Next three bands of PEG 20,000/DPD conjugate
(0.85 mg/mL of PBS) were deposited on the same nitrocellulose
membrane at about 1, 1.5 and 2 cm from its bottom in amounts
of 2 yL/cm, 1 yL/cm and 1 yL/cm respectively. The nitrocellu-
lose membrane was dried, blocked with casein solution (1% in
PBS), washed with water and then dried at ambient conditions.
The nitrocellulose membrane was mounted on a polystyrene
backing using an acrylic based adhesive. A gold sol/anti-DPD
antibody pad 12 was then mounted at the position shown in Fig.
1 followed by the addition of an absorbant pad. This piece of
CA 022~2141 1998-10-26
the assembly was then slit into 4.2'' (10.7 cm) by 0.2" (5.1
cm) strips.
For testing, the strips were dipped into a test tube con-
taining the test solution, i.e. an aqueous solution containing
various low molecular weight substances known to be present in
urine as well as seven levels (0, 10, 25, 50, 75, 150 and 250
mM) DPD. After the liquid had reached the top of the nitro-
cellulose membrane, the strip was removed from the test tube
and scanned for response with a CLINITEK~ 50 reflectance spec-
trometer. The % reflectance at each of the five bands was
measured and recorded. As shown in Fig. 2, a dose response
curve was generated using the method of the present invention.
This dose response curve illustrates that the technique of the
present invention can successfully determine the concentration
of DPD over the concentrations demonstrated.
The foregoing discussion has centered on deoxypyridino-
line (DPD) as the analyte. However, the present invention is
not limited to this particular analyte. Other small analytes,
particularly those with molecular weights of less than about
1500, can be immobilized by the technique of the present in-
vention. Examples of such analytes include digoxin, drugs of
abuse such as thyroxine and anticonvulsant drugs such as phen-
ylbarbitol, phenytoin and carbamazepine. The immobilization
of DPD is particularly challenging because certain anti-DPD
antibodies will not consistently recognize DPD immobilized by
conventional BSA techniques. This lack of consistency is ob-
viated by the present invention as illustrated by the data
presented in Table 1.
